[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"osteo-arthritis-of-the-knee\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:osteo-arthritis-of-the-knee":450},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,17,0,[8,44,70,97,118,146,169,198,219,243,273,295,317,339,365,395,422],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":21,"briefSummary":23,"conditions":24,"keywords":26,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100642023",false,"NCT07657481","Comparison of the Effects of Two Different Exercise Programs on Femoral Cartilage Thickness and Clinical Parameters in Individuals With Knee Osteoarthritis","Comparison of the Effects of Two Different Home Exercise Programs on Femoral Cartilage Thickness and Clinical Parameters in Individuals With Knee Osteoarthritis: A Randomized Controlled Trial","Inclusion Criteria:\n\n1. Age ≥18 years\n2. Diagnosis of knee osteoarthritis according to ACR criteria, Kellgren-Lawrence grade 2-3\n3. Knee pain for at least 3 months\n4. Having the physical capacity to perform a home exercise program\n5. Willingness to provide written informed consent\n\nExclusion Criteria:\n\n1. History of knee, hip, or spine surgery\n2. Active inflammatory arthritis (e.g., rheumatoid arthritis, gout, psoriatic arthritis)\n3. Intra-articular injection within the last 3 months\n4. Neurological or neuromuscular disorders\n5. Body mass index (BMI) \\> 40 kg\u002Fm²\n6. Pregnancy\n7. Cardiovascular or orthopedic contraindications preventing participation in a regular exercise program\n8. Cognitive impairment","ALL","18 Years",{"count":18,"type":19},56,"ESTIMATED","INTERVENTIONAL",[22],"NA","Knee osteoarthritis (OA) is one of the most common joint disorders worldwide and is a leading cause of pain, limited mobility, and functional disability, particularly in the elderly population. According to 2020 data, approximately 654 million individuals aged 40 years and older are affected by knee OA worldwide, with a global prevalence of 22.9% in this age group. In our country as well, OA is reported as the second most common rheumatologic disease. The disease not only negatively affects individuals' quality of life but also creates a significant socioeconomic burden through work loss, hospital admissions, and the need for surgical interventions.\n\nThe pathogenesis of knee OA is a complex process involving articular cartilage degeneration, subchondral bone sclerosis, synovial tissue proliferation, and osteophyte formation. Once cartilage damage begins, its capacity for spontaneous healing is extremely limited; therefore, early interventions aimed at slowing or halting disease progression are of critical importance. In this context, non-pharmacological interventions, particularly exercise programs that may contribute to maintaining cartilage integrity, are strongly recommended as first-line treatment options in current clinical guidelines.\n\nThe beneficial effects of exercise therapy on pain and function in patients with knee OA are well documented. However, the structural effects of exercise on femoral cartilage thickness have been relatively less investigated. Tuna et al. evaluated femoral cartilage thickness using ultrasonography in 40 patients with knee OA following a 12-week quadriceps strengthening program and reported statistically significant increases in cartilage thickness in the medial condyle, lateral condyle, and intercondylar region at 3 months. This pioneering study suggests that muscle strengthening programs may have not only symptomatic but also structural benefits. Similarly, Bozan et al. reported a strong positive correlation between quadriceps muscle thickness (rectus femoris + vastus intermedius) and femoral cartilage thickness, supporting the idea that muscle loss parallels cartilage degeneration. However, these studies focused exclusively on the quadriceps muscle, and the effects of hip musculature on femoral cartilage thickness have not been investigated. Recent biomechanical studies indicate that hip abductor and adductor muscles play a critical role in knee joint loading patterns.\n\nHip abductor muscles provide pelvic stability during gait and directly influence knee adduction moments. Weakness of the gluteus medius leads to contralateral pelvic drop, increasing medial compartment loading on the ipsilateral knee and accelerating medial tibiofemoral cartilage wear. Indeed, Segal et al., using data from the Multicenter Osteoarthritis Study (MOST), demonstrated via MRI that greater hip abductor strength significantly reduces the risk of progression of medial patellofemoral and lateral tibiofemoral cartilage damage. On the other hand, hip adductor muscles are also thought to contribute to knee adduction moments by eccentrically controlling femoral varus motion; however, this relationship has been studied far less compared to quadriceps and abductors.\n\nSystematic reviews and meta-analyses have shown that individuals with knee OA have up to 24% lower isometric hip abductor strength compared to healthy controls. Randomized controlled trials investigating combined hip and quadriceps strengthening programs have reported significant improvements in pain and function. However, none of these studies have used femoral cartilage thickness measured by ultrasonography as a primary outcome.\n\nA review of the current literature reveals that although studies exist examining the effects of quadriceps strengthening on femoral cartilage thickness, no randomized controlled trial has compared hip abductor and adductor strengthening exercises with a quadriceps strengthening program, using ultrasonographic femoral cartilage thickness as the primary outcome measure. This study aims to address this gap. All interventions will be applied as non-invasive home exercise programs, and all measurements will be performed using ultrasonography. Baseline, 1-month, and 3-month assessments will also allow evaluation of the temporal effects of exercise on cartilage structure. The findings are expected to provide scientific evidence regarding the structural protective effects of hip exercises in knee OA rehabilitation and serve as pilot data for future large-scale multicenter studies.\n\nThe aim of this study is to compare patients with knee OA receiving quadriceps strengthening exercises alone with those receiving additional hip abductor\u002Fadductor strengthening exercises in terms of changes in femoral cartilage thickness, and to evaluate whether there is a correlation between femoral cartilage thickness and the thickness of the rectus femoris, gluteus medius,",[25],"Osteo Arthritis of the Knee",[27,28,29,30],"knee osteoartritis","femoral cartilage thikness","quadriceps strengthening exercises","hip abductor and adductor strengthening exercises","NOT_YET_RECRUITING","2026-06-17",{"date":34,"type":35},"2026-06-22","ACTUAL",{"date":37,"type":19},"2026-08-20",{"date":39,"type":19},"2027-07-01",{"name":41,"class":42},"Pamukkale University","OTHER",1,{"id":45,"slug":4,"hasResults":10,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":4,"eligibilityCriteria":49,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":50,"enrollmentInfo":51,"targetDuration":4,"studyType":20,"phases":53,"briefSummary":55,"conditions":56,"keywords":58,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":4},"100643251","NCT07646158","Alignment Techniques in TKA RCT","Investigating Alignment Techniques in Total Knee Arthroplasty for Morbid Obese Patients: Randomize Control Trial.","Inclusion Criteria:\n\n* Being an adult (age \\>= 18 years)\n* Being indicated for Total Knee Arthroplasty (TKA) for the treatment of non-inflammatory knee osteoarthritis by the PI or sub-investigators.\n* Having a body mass index (BMI) \\>= 35 kg\u002Fm2\n\nExclusion Criteria:\n\n* Patients who are unable to provide written consent\n* Being under-age (age \\\u003C 18 years)\n* Having a BMI \\\u003C 35 kg\u002Fm2\n* Having a non-elective TKA\n* Having a diagnosis of secondary or inflammatory, rheumatic, psoriatic, osteoarthritis of the index knee\n* Having a local or widespread infection\n* Being pregnant - Women who become pregnant at any point throughout the research study will become excluded\u002Fineligible and will immediately stop all study activities.\n* Women who are capable of becoming pregnant and not currently on contraceptives will be excluded from this study because it will be difficult to obtain the weightbearing CT using the standard CT shield for pregnant women.\n* Having had a previous open surgery of the index knee\n* Presence of local or widespread infection\n* Having a revision TKA\n* Having a simultaneous bilateral TKA\n* Not being able to safely conduct study procedures - If patients are wheelchair bound or require an assistive device to stand for 5 minutes, they will be excluded from this study.\n* Non-English speakers\n* Prisoners","100 Years",{"count":52,"type":19},80,[54],"PHASE4","The purpose of this research study is to compare two different methods used to align the knee during a total knee arthroplasty (TKA): technology-assisted inverse kinematic alignment, and manual-instrumented gap balancing alignment. The first technique uses robotic or computer-assisted technology to help the surgeon place the knee implant based on the patient's individual anatomy, whereas the manual technique uses standard surgical instruments and manual methods to position and balance the knee implant during surgery. The main difference is that one approach uses robotic or computer assistance to help guide implant positioning, while the other uses traditional instruments and manual surgical techniques. Both methods are commonly used and are considered standard care. The goal of this study is to understand whether one method results in better knee motion, function, and recovery after surgery in patients with higher body weight.",[25,57],"Obesity & Overweight",[59,60],"Osteoarthritis","Obesity","2026-06-08",{"date":63,"type":35},"2026-06-12",{"date":65,"type":19},"2026-07-01",{"date":67,"type":19},"2029-12-31",{"name":69,"class":42},"Jacob M. Elkins",{"id":71,"slug":4,"hasResults":10,"nctId":72,"briefTitle":73,"officialTitle":74,"acronym":75,"eligibilityCriteria":76,"healthyVolunteers":10,"sex":15,"minAge":77,"maxAge":4,"enrollmentInfo":78,"targetDuration":4,"studyType":20,"phases":80,"briefSummary":81,"conditions":82,"keywords":83,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":88,"startDateStruct":90,"completionDateStruct":92,"leadSponsor":94,"locationsCount":43},"100637376","NCT07611708","Lubricin-inspired Osteoarthritis Treatment: a Unique Solution","First in Human Safety Evaluation of a Novel Polymer for Knee Osteoarthritis","LOTUS","Inclusion Criteria:\n\n1. Male or female at least 40years of age\n2. Knee OA with Kellgren-Lawrence (KL) Grade 2 to 4 of the target knee on X-ray\n3. Inadequate pain relief with 1st line treatment, consisting of any of the following\n\n   1. conservative non-pharmacological treatment AND\u002FOR\n   2. stable dose NSAIDs for at least the past 30 days OR\n   3. use of NSAID treatment is contraindicated\n4. Target knee pain on most days (at least 15 days per month in the preceding month)\n5. Symptomatic knee OA with moderate to severe pain (NRS ≥4 and \\\u003C9 on Numeric Rating Scale (NRS) with target knee significantly worse than the other knee with a minimum difference of 2-point between knees.\n6. Possess cognitive and language ability to complete informed consent and questionnaires\n7. Willingness to follow protocol instructions and maintain appointment schedule of the study\n8. Willingness to maintain their existing stable regimen (defined as the same regimen for at least the past 30 days) of complementary and non-pharmacological knee OA treatments for trial duration (if any)\n9. If participant is taking a stable regimen of NSAIDs - they are willing to maintain their existing stable regimen (defined as taking the same dose for at least the past 30 days) of NSAIDs and not anticipate to change for the duration of the study.\n10. Willingness to stop any 'as needed' (PRN) NSAIDs or paracetamol or opioids (except for protocol-permitted rescue pain medication) for the duration of the trial\n11. Willingness to stop taking any rescue pain meds 24 hours prior to scheduled follow up clinic visits (except for their stable NSAIDs therapy)\n\nExclusion Criteria:\n\n1. Pregnant or lactating\n2. Other significant knee pathologies of target knee from medical history or radiographic method(s)\n3. Severe malalignment \\> 10 degree in the target knee (either varus or valgus) measured using standardized knee x-ray at screening or based on previous medical records\n4. Severe inflammatory arthritis or other joint disease with warm, red, and swollen knee in the target knee\n5. History of knee surgery or significant knee trauma of target knee in the past 12 months\n6. Received intraarticular injection in the targeted knee joint within the past 6 months\n7. Knee surgery or intraarticular injection in the target knee planned in the next 8 months\n8. Allergy to rescue pain medication (paracetamol)\n9. Unstable\u002F poorly controlled coagulopathy\\[CH1.1\\]\\[LC1.2\\]\n10. Severe anxiety, depression or psychiatric disorder based on self -reported medical history\n11. Chronic pain conditions other than knee OA (e.g. cancer, fibromyalgia, pain due to hip OA, etc.) which may interfere with the outcomes of the study, at the discretion of the investigator\n12. History of or current substance abuse, self-reported\n13. Significant systemic medical comorbidities, e.g. uncontrolled diabetes or hypertension, immunocompromised, cancer, severe cardiovascular disease, neuropathic pain\u002Fdisorder, etc.\n14. ModifiedPainDETECT Questionnaire (mPDQ) \\>18\n15. Current use of any non-opioids centrally acting analgesics including gabapentin, pregabalin, duloxetine, tricyclic antidepressants (e.g. amitriptyline) for pain management within 12 weeks prior to screening.\n16. Started taking oral or injectable GLP-1 products in the past 6 months as new regimen. Current use of a GLP-1 product is permitted if the participant has been on the product for \\> 6 months and plans to continue the product at its current stable dose for the duration of the trial.\n17. Started taking another concomitant medication within the past 12 weeks or changed dose of a concomitant medication within the past 12 weeks which could, in the opinion of the Principal Investigator or delegate, impact the participant's safety on the trial or the reliability of the outcome assessments.\n18. Participate in another clinical trial and received study intervention currently or in the past 3 months","40 Years",{"count":79,"type":19},25,[22],"This goal of this open label study is to evaluate the safety and tolerability of a single intra-articular administration of ABR1 in adults with knee osteoarthritis with a KL grade from 2 to 4. The primary questions it aims to answer are:\n\n1. Is ABR1 safe to use as an intraarticular injection for participants with knee osteoarthritis?\n2. What medical problems do participants have after receiving a single injection of ABR1?\n\nParticipants will receive a single injection of ABR1 to the knee with osteoarthritis. Participants will\n\n1. Keep a stable pain treatment regimen\n2. Visit the clinic at 1 week, 4 weeks, 8 weeks, and 12 weeks post injection\n3. Keep a diary of their symptoms and number of times they use a rescue medication for their knee pain.",[25],[84,85,86],"knee pain","intra articular","lubrication","2026-05-27",{"date":89,"type":35},"2026-05-29",{"date":91,"type":19},"2026-08",{"date":93,"type":19},"2027-12",{"name":95,"class":96},"Pleryon Therapeutics (Hangzhou) Limited","INDUSTRY",{"id":98,"slug":4,"hasResults":10,"nctId":99,"briefTitle":100,"officialTitle":101,"acronym":4,"eligibilityCriteria":102,"healthyVolunteers":10,"sex":15,"minAge":4,"maxAge":4,"enrollmentInfo":103,"targetDuration":4,"studyType":20,"phases":105,"briefSummary":106,"conditions":107,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":109,"lastUpdatePostDateStruct":110,"startDateStruct":112,"completionDateStruct":114,"leadSponsor":116,"locationsCount":4},"100635315","NCT07551089","Kinematic vs Mechanical Alignment in High Tibial Osteotomy","The Short Term Outcome of Kinematic Versus Mechanichal Alignment After High Tibial Osteotomy for Varus Osteoarthritic Knee : A Prospective Randomized Controlled Trial","Inclusion Criteria:\n\n* Clinical: 1. Age : Adult with symptomatic osteoarthritic varus knee 2-Medial knee pain with functional limitation ≥6 months despite optimized non-operative care.\n\nRadiological: 1- Medial compartment OA in Xray AP-Lateral view 2-Degree of varus ≥3 and ≤15 degree in long film(full-length, standing hip-to-ankle radiographs) 3-•Varus knee (mpta ≤85 degree and ldfa ≤93 and jlca ≤5)\n\nPhysical : 1-Range of motion: Flexion ≥110°, flexion contracture ≤10°, extension lag ≤5°.\n\n2-Gait testing: Able to walk unaided (or with standard aid) for instrumented gait analysis.\n\nExclusion Criteria:\n\n* 1- Predominantly lateral compartment OA 2- severe patellofemoral arthritis 3- Prior high tibial osteotomy, knee arthroplasty, or complex fracture around the knee 4-Inflammatory arthropathies (eg, rheumatoid arthritis) 5- end stage medial compartment osteoarthritis with bone erosions 6-chondrocalcinosis",{"count":104,"type":19},100,[22],"To compare between kinematic and mechanichal alignment after High Tibial Osteotomy (clinically and radiologically)",[25,108],"Genu Varum","2026-05-21",{"date":111,"type":35},"2026-05-26",{"date":113,"type":19},"2026-06-01",{"date":115,"type":19},"2029-10-01",{"name":117,"class":42},"Assiut University",{"id":119,"slug":4,"hasResults":10,"nctId":120,"briefTitle":121,"officialTitle":122,"acronym":123,"eligibilityCriteria":124,"healthyVolunteers":10,"sex":15,"minAge":125,"maxAge":126,"enrollmentInfo":127,"targetDuration":4,"studyType":20,"phases":129,"briefSummary":130,"conditions":131,"keywords":132,"overallStatus":135,"whyStopped":4,"lastUpdateSubmitDate":136,"lastUpdatePostDateStruct":137,"startDateStruct":139,"completionDateStruct":141,"leadSponsor":143,"locationsCount":145},"100632651","NCT07516457","Hydrogel Assessment for Local Treatment of Osteoarthritis","A Prospective, Multi-Center, Open-Label Study to Evaluate the Safety and Tolerability of Hydrogel OA 2% in Patients With Knee Osteoarthritis","HALO","Inclusion Criteria:\n\n1. Adults accepting to participate in the study and having signed the written informed consent form before any protocol-specific procedures and able to understand and follow the instructions as described in the protocol.\n2. Unilateral symptomatic tibiofemoral KOA confirmed by a \"stand-ing knee\" X-ray. In case of bilateral KOA on X-ray only one knee (index knee) presents symptomatic OA pain.\n3. Age 35 ≤ 75 years.\n4. BMI 20 ≤ 35.\n5. Knee Injury and Osteoarthritis Outcome Score (KOOS) Pain score 25 ≤ 70.\n6. Patients impacted by pain in the index knee during daily activi-ties.\n7. Radiological Kellgren and Lawrence (K\\&L) grade II and III of the index knee from a standing knee radiograph assessed during the screening visit, using the most recent X-ray taken either im-mediately or within the past 3 months.\n8. Fully ambulatory for functional assessments.\n9. Willingness to refrain from taking any pain medication for 48 hours prior to investigational device injection on day 0.\n10. Female subjects must be on effective contraception (pill, patch, ring, diaphragm, implant or intrauterine device) and must perform a pregnancy test, of which the result must be negative, at the treatment visit unless they are surgically sterile (tubal ligation or hysterectomy) or postmenopausal for at least one year.\n\nExclusion Criteria:\n\n1. Bilateral tibiofemoral KOA where the non-index knee presents a worse radiological grade of KOA than the index knee.\n2. Significant clinically assessed varus or valgus deformation of the selected knee side of more than 10 degrees.\n3. Extension deficit of the index knee higher than 5 degrees.\n4. Bilateral symptomatic tibiofemoral KOA or combined ipsilateral symptomatic tibiofemoral knee and hip OA.\n5. Clinical signs of significant effusion with noticeable swelling and\u002For inflammation related to severe pain.\n6. Active lymphatic or venous stasis or serious blood disorders (e.g., anemia), bleeding disorders (e.g., hemophilia), blood clots, or blood cancers (e.g., leukemia, lymphoma, and myeloma).\n7. Active bacterial infection, resulting in hospitalization and\u002For requiring intravenous antibiotic treatment.\n8. Synovial infection, skin infection or skin diseases in the area of the injection site.\n9. History of autoimmune diseases that causes chronic joint pain and inflammation in the knee joint, including rheumatoid arthritis, psoriasis arthritis, juvenile idiopathic arthritis, systemic lupus erythematosus, gout, pseudogout, systemic sclerosis, Sjögren's disease, adult-onset still's disease.\n10. Known or suspected generalized chronic pain disorder.\n11. Severe alteration of mobility preventing any functional assessment.\n12. Allergy or hypersensitivity to any of the product components of Hydrogel OA 2%.\n13. Conditions (orthopedic, rheumatologic, musculoskeletal or inflammatory) causing symptomatic and\u002For radiating pain in the lower extremities that might interfere with the symptomatic OA knee pain, including hip OA assessed by physical examination by the physician.\n14. Symptomatic patellofemoral knee OA.\n15. Oral corticotherapy in the last 3 months before injection of the investigational device.\n16. Regular\u002Fchronic use of opioid drugs in the last 3 months before injection. Use of any opioid drug during the last 7 days prior to injection of the investigational device.\n17. Severe acute illness within 14 days prior to injection of the investigational device.\n18. Pain Catastrophizing Scale score of 30 or higher.\n19. Any intra-articular injection (hyaluronan, hydrogel, soft implant, corticosteroid, platelet-rich plasma, local anesthetic etc.) arthroscopy, surgery in the index knee; or cell-based therapy or an invasive procedure on the index knee in the last 6 months before injection of the investigational device.\n20. Anticipated need for any surgical or other invasive procedure in the index knee throughout the course of the clinical investigation, including prosthesis and\u002For any concurrent OA treatments including alternative treatments.\n21. Any investigator-assessed clinically significant condition that may represent a substantial risk to the patient or may have an impact on the study assessments.\n22. Participation in another clinical trial in the last 3 months before injection of the investigational device.\n23. Pregnancy and breastfeeding.\n24. Legal incapacity or limited legal capacity to consent.\n25. Trauma of the index knee in the last 6 months before injection of the investigational device.","35 Years","75 Years",{"count":128,"type":19},20,[22],"The study aims to evaluate the safety and tolerability of one intra-articular injection of Hydrogel OA 2% for the symptomatic treatment of osteoarthritis of the knee.",[25],[133,134],"osteoarthritis","knee","RECRUITING","2026-05-06",{"date":138,"type":35},"2026-05-11",{"date":140,"type":19},"2026-04",{"date":142,"type":19},"2027-09-30",{"name":144,"class":96},"Allegro NV\u002FSA",3,{"id":147,"slug":4,"hasResults":10,"nctId":148,"briefTitle":149,"officialTitle":150,"acronym":151,"eligibilityCriteria":152,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":153,"targetDuration":4,"studyType":20,"phases":155,"briefSummary":156,"conditions":157,"keywords":158,"overallStatus":135,"whyStopped":4,"lastUpdateSubmitDate":160,"lastUpdatePostDateStruct":161,"startDateStruct":163,"completionDateStruct":165,"leadSponsor":167,"locationsCount":43},"100619871","NCT07350252","Combination of Nerve Blocks and Local Infiltration Analgesia in Knee Arthroplasty","Postoperative Analgesia in Patients Undergoing Knee Replacement Surgery - a Study Comparing Intraoperative Local Infiltration Analgesia Only With Ultrasound-guided Nerve Blocks Added to Intraoperative Local Infiltration Analgesia, a Randomized Clinical Trial","BALIA","Inclusion Criteria:\n\n-Undergoing primary unilateral total knee arthroplasty\n\nExclusion Criteria:\n\n* Pregnancy\n* Coagulopathy or other bleeding disorder that precludes regional anesthesia\n* Allergy to local anesthetics\n* Inability to understand spoken and written Swedish\n* Unwillingness to participate in the study",{"count":154,"type":19},200,[54],"The aim of this clinical randomized trial is to compare local infiltration analgesia (LIA) alone versus the combination of LIA with saphenous nerve (SN) block, block of the nerve to vastus medialis (NVM), and anterior femoral cutaneous nerve (AFCN) block in participants undergoing total knee arthroplasty (TKA). The primary outcome is pain intensity, measured using the Numerical Rating Scale (NRS) at multiple time points after surgery. Secondary outcomes include opioid consumption, time to mobilization, postoperative nausea and vomiting, length of hospital stay, neurological complications and differences in opioid consumption and NRS pain scores between general and spinal anesthesia.",[25],[159],"Treatment","2026-05-04",{"date":162,"type":35},"2026-05-08",{"date":164,"type":35},"2026-03-05",{"date":166,"type":19},"2027-09-01",{"name":168,"class":42},"Region Skane",{"id":170,"slug":4,"hasResults":10,"nctId":171,"briefTitle":172,"officialTitle":173,"acronym":174,"eligibilityCriteria":175,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":176,"targetDuration":4,"studyType":20,"phases":178,"briefSummary":179,"conditions":180,"keywords":186,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":190,"lastUpdatePostDateStruct":191,"startDateStruct":192,"completionDateStruct":193,"leadSponsor":195,"locationsCount":43},"100635374","NCT07551856","Manual Arthroplasty Versus VELYS Robotic-Assisted Solution Functional Alignment Arthroplasty for Knee Osteoarthritis","Manual Arthroplasty Versus VELYS Robotic-Assisted Solution Functional Alignment Arthroplasty for Knee Osteoarthritis (The MARVEL Project): A Pragmatic, Multicentre, Blinded Randomised Controlled Trial With Multi-domain Investigations","MARVEL Project","Inclusion Criteria:\n\n* Aged \\>18 years\n* Primary knee OA\n* Requiring TKA\n* Suitable for either raTKA or mTKA\n* Capable to provide written informed consent\n* Capable and willing to complete outcome measures throughout study period\n\nExclusion Criteria:\n\n* Inflammatory arthritis\n* Significant symptomatic hip, ankle, or contralateral knee OA\n* Prior TKA or major injury or major surgery on the index knee\n* Neuromuscular gait disorders\n* BMI \\>45 kg\u002Fm2\n* Coronal plane deformity \\>15° varus\u002Fvalgus on pre-op HKA radiograph\n* Fixed flexion deformity greater than 15°\n* Bone loss likely to require non-standard implants (e.g. stems, augments)\n* Severe deformity or ligament insufficiency likely to require constraint\n* Inability to comply with the required follow-up assessments or complete PROMs\n* Contraindications to any aspect of the surgical technique",{"count":177,"type":19},346,[22],"The goal of this clinical trial is to learn if the VELYS Robotic-Assisted Solution (VRAS) device helps to improve outcomes from total knee replacement, when compared to regular non-robotic-assisted total knee replacement in the treatment of osteoarthritis. It will also aim to review the longer-term safety and efficiency effects of using this device.\n\nThe main questions it aims to answer are:\n\n1. Does VRAS device-assisted total knee replacement improve patient outcomes (such as their function, satisfaction, and pain) when compared to non-robotic-assisted total knee replacement?\n2. Does VRAS device-assisted total knee replacement improve clinical outcomes (such as revision risk, complications, and hospital length of stay) when compared to non-robotic-assisted total knee replacement?\n3. Does VRAS device-assisted total knee replacement improve functional outcomes (including biomechanical motion analysis) when compared to non-robotic-assisted total knee replacement?\n4. What are the economic and efficiency effects of VRAS device-assisted total knee replacement compared to non-robotic-assisted total knee replacement?\n5. What are the human factor and learning curve effects of introducing VRAS device-assisted total knee replacement into healthcare teams?\n6. Are there any differences in safety and adverse event incidence between VRAS device-assisted total knee replacement and non-robotic-assisted total knee replacement?\n\nParticipants will:\n\n* Be randomised to receive a total knee replacement using either regular non-robotic-assisted methods, or with the use of the VRAS device.\n* Be assessed pre-operatively at the clinic, and then at 6 weeks, 6 months, and 12 months following date of operation. At these appointments patients will answer questionnaires, receive an x-ray (pre-operatively, and at 6 months post-operatively), and a subgroup will be reviewed in the motion analysis laboratory (pre-operatively, and at 6 months post-operatively).\n* Have their longer-term outcomes including any revision operations monitored out to 10 years through national registry data linkage (no actual follow-up for patients after 12 months).",[181,182,25,183,184,59,185],"Knee Osteoarthritis","Osteoarthritis (Knee)","Osteo Arthritis","Osteoarthritis (OA)","Osteoarthritis in the Knee",[187,59,188,189],"Knee","Robotic","Alignment","2026-04-28",{"date":160,"type":35},{"date":162,"type":19},{"date":194,"type":19},"2030-05-08",{"name":196,"class":197},"Golden Jubilee National Hospital","OTHER_GOV",{"id":199,"slug":4,"hasResults":10,"nctId":200,"briefTitle":201,"officialTitle":201,"acronym":4,"eligibilityCriteria":202,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":50,"enrollmentInfo":203,"targetDuration":4,"studyType":204,"phases":4,"briefSummary":205,"conditions":206,"keywords":207,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":190,"lastUpdatePostDateStruct":212,"startDateStruct":213,"completionDateStruct":215,"leadSponsor":217,"locationsCount":43},"100635524","NCT07553806","Evaluating the Clinical Impact of the Prehabilitation and Recovery for Enabling Potential (PREP) Clinical Care Pathway","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Must be a Veteran under the clinical care of an RJAH Veterans Orthopaedic Consultant and participating in the PREP Programme.\n* Able to read and speak English.\n* Able to demonstrate capacity to provide informed consent.\n\nExclusion Criteria:\n\n* Subject is under 18 years of age.\n* Subject is not a Veteran, not under the care of an RJAH Veteran's Orthopaedic Consultant, or is not participating in the PREP Programme.\n* Unable to read and speak English.\n* Unable to demonstrate capacity to provide informed consent.\n* Unable, or unwilling to complete questionnaires throughout the duration of the study.",{"count":52,"type":19},"OBSERVATIONAL","The Evaluating PREP Study aims to determine in whether the PREP Programme has an impact on clinical outcomes for Veterans undergoing TKR. Specifically, we are exploring whether prehabilitation and a week long intense individualised rehabilitation period after TKR surgery has a positive impact on functional and mental outcomes, and whether these are sustained for up to 12 months post-surgery.",[25],[208,209,210,211],"Physiotherapy","Prehabilitation","Rehabilitation","Outcome",{"date":160,"type":35},{"date":214,"type":19},"2026-05",{"date":216,"type":19},"2028-05",{"name":218,"class":197},"Robert Jones and Agnes Hunt Orthopaedic and District NHS Trust",{"id":220,"slug":4,"hasResults":10,"nctId":221,"briefTitle":222,"officialTitle":222,"acronym":4,"eligibilityCriteria":223,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":224,"enrollmentInfo":225,"targetDuration":4,"studyType":20,"phases":227,"briefSummary":228,"conditions":229,"keywords":230,"overallStatus":135,"whyStopped":4,"lastUpdateSubmitDate":235,"lastUpdatePostDateStruct":236,"startDateStruct":237,"completionDateStruct":239,"leadSponsor":241,"locationsCount":43},"100602979","NCT07130552","Comparison of Distal IPACK and Popliteal Plexus Block Combined With Femoral Triangle Block After Total Knee Arthroplasty","Inclusion Criteria:\n\n* Patients undergoing total knee arthroplasty under spinal anesthesia\n* American Society of Anesthesiologists (ASA) status I-III\n* Patients who give informed consent\n\nExclusion Criteria:\n\n* Patients unable to cooperate\n* Kidney disease with GFR \\\u003C 50 ml\u002Fmin\n* Daily opioid consumption \\> 1 month\n* Allergy to local anesthetics\n* Neurological problems of the lower extremity\n* Contraindications to peripheral nerve blocks","85 Years",{"count":226,"type":19},120,[22],"This study aims to investigate the effect of femoral triangle block combined with popliteal plexus block and distal IPACK block on postoperative pain after total knee arthroplasty (TKA)",[25],[231,232,233,234],"Total knee arthroplasty","popliteal plexus block","femoral triangle block","iPACK block (infiltration of the interspace between the popliteal artery and the posterior knee capsule)","2026-04-25",{"date":190,"type":35},{"date":238,"type":35},"2025-08-29",{"date":240,"type":19},"2026-09-30",{"name":242,"class":42},"Karaman Training and Research Hospital",{"id":244,"slug":4,"hasResults":10,"nctId":245,"briefTitle":246,"officialTitle":247,"acronym":4,"eligibilityCriteria":248,"healthyVolunteers":249,"sex":15,"minAge":250,"maxAge":224,"enrollmentInfo":251,"targetDuration":4,"studyType":20,"phases":253,"briefSummary":255,"conditions":256,"keywords":258,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":263,"lastUpdatePostDateStruct":264,"startDateStruct":266,"completionDateStruct":268,"leadSponsor":270,"locationsCount":272},"100632606","NCT07515872","Long Duration High Frequency Ultrasound for the Treatment of Osteoarthritis","Sustained Acoustic Medicine (SAM) for Symptomatic Treatment of Knee Pain Related to Osteoarthritis","Inclusion Criteria:\n\n* Have physician-diagnosed mild to moderate knee OA (OARSI atlas grades 1-2)\n* Fulfill the American College of Rheumatology clinical and radiological diagnostic criteria for knee OA\n* Are between 65-85 years of age\n* Report a frequent pain score between 4-7 (range: 0-10) during the week preceding enrollment\n* Report that knee pain negatively affects quality of life\n* Are willing not to use any cream, gel, or topical solution during the administration of treatment other than the approved ultrasound gel provided to the subject at the initiation of the study\n* Are deemed appropriate by their physician or by the study site physician to participate.\n* Be willing and able to self-administer treatment daily within their place of residence or during normal daily activity, excluding bathing, showering, or other water activities which may result in submersion of the study device.\n* Not use or initiate use of opioid and\u002For non-opioid analgesic medications.\n* Be willing to discontinue any other interventional treatment modalities on the knee during the study period (e.g., transcutaneous electrical nerve stimulation, electronic muscle stimulation, traditional ultrasound).\n\nExclusion Criteria:\n\n* Cannot successfully demonstrate the ability to put on and take off the device.\n* Displays any condition which, in the judgment of the investigator, would make participation in the study unacceptable including, but not limited to, the subject's ability to understand and follow instructions.\n* Participated in a clinical trial for an investigational drug and\u002For agent within 30 days prior to screening.\n* Is pregnant.\n* Is a prisoner.\n* Is non-ambulatory (unable to walk).\n* Has a pacemaker.\n* Has a malignancy in the treatment area.\n* Has an active infection, open sores, or wounds in the treatment area.\n* Has impaired sensation in the treatment area, such as caused by chemotherapy or anesthesia.\n* Has a known neuropathy (disease of the brain or spinal nerves).\n* Has a hereditary disposition (tendency) for excessive bleeding (hemorrhage).\n* Have knee replacement, other surgical intervention, or hyaluronidase injection in the affected knee in the past 6 months.\n* Are currently taking steroids.\n* Have any contraindication to radiograph.\n* Have a secondary cause of arthritis (metabolic or inflammatory).\n* Have a known contraindication, allergy, or hypersensitivity to corticosteroids or any component of Kenalog®-40 (if assigned to the injection group).",true,"65 Years",{"count":252,"type":19},240,[254],"PHASE2","The purpose of this study is to assess the ability of long-duration high-frequency continuous-wave therapeutic ultrasound to alleviate knee Osteoarthritis pain over an 12-week period. The primary objective of this study is to evaluate the analgesic effect of ultrasound treatment in subjects suffering from knee Osteoarthritis pain. Secondary objectives are to assess the ability of ultrasound treatment to improve joint function.",[257,25],"Arthritis",[259,260,261,262],"high-frequency continuous ultrasound","sustained acoustic medicine","low-intensity continuous ultrasound","wearable long duration ultrasound","2026-03-31",{"date":265,"type":35},"2026-04-07",{"date":267,"type":19},"2026-05-01",{"date":269,"type":19},"2028-05-31",{"name":271,"class":96},"ZetrOZ, Inc.",2,{"id":274,"slug":4,"hasResults":10,"nctId":275,"briefTitle":276,"officialTitle":277,"acronym":4,"eligibilityCriteria":278,"healthyVolunteers":249,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":279,"targetDuration":4,"studyType":20,"phases":281,"briefSummary":282,"conditions":283,"keywords":4,"overallStatus":135,"whyStopped":4,"lastUpdateSubmitDate":287,"lastUpdatePostDateStruct":288,"startDateStruct":290,"completionDateStruct":292,"leadSponsor":293,"locationsCount":43},"100631094","NCT07496203","The Effectiveness of BETY in Knee Osteoarthritis With Intra-Articular Injections","An Investigation of the Effectiveness of the BETY Exercise Program, Based on the Biopsychosocial Model, in Individuals With Knee Osteoarthritis Who Have Received Intra-articular Injections","Inclusion Criteria:\n\n* Diagnosis of knee osteoarthritis according to ACR knee osteoarthritis diagnostic criteria\n* Being in stage 2 or 3 according to Kellgren-Lawrence radiological staging criteria\n* having received an intra-articular injection in the knee within the past month\n* To be 18 years of age or older\n* Being a reader-writer\n* Having read and signed the informed consent\n\nExclusion Criteria:\n\n* History of major psychiatric illness\n* Having malignant disease\n* Having chronic infectious or other rheumatologic diseases\n* Serious knee trauma or surgical operation in the last 6 months\n* Having collagen tissue disease\n* History of peripheral vascular disease or neuropathy\n* Being in stage 4 according to Kellgren Lawrence radiologic staging criteria\n* To have received a physiotherapy program for the relevant knee in the last 3 months",{"count":280,"type":19},60,[22],"Osteoarthritis (OA) is the most common condition in middle-aged and elderly populations; it causes pain and physical disability and is characterized by cartilage degeneration, changes in bone tissue, inflammation of the synovial membrane, and an increased inflammatory response. Because pain and depression often co-occur in individuals diagnosed with OA, the concepts of disability and health-related quality of life caused by the disease have become more decisive than radiological joint damage. The chronic nature of the disease, like other chronic conditions, encompasses a range of biopsychosocial impacts, including pain, fatigue, sleep disturbances, functional loss, anxiety, depression, and social isolation. This complex structure is accompanied by a pattern in which inflammatory processes are triggered. Recently, intra-articular injections (such as Platelet-Rich Plasma Therapy (PRP), Hyaluronic Acid (HA), PRP+HA combinations, Corticosteroids, Prolotherapy, and Stem Cells) have been accepted as a treatment for OA. Regarding the mechanism of these intra-articular injections, it has been reported that a combination of various anabolic and anti-inflammatory cytokines may treat inflammation associated with the early stages of OA. It has been demonstrated that, through the effects of various growth factors, these treatments have a positive impact on chondrogenesis and mesenchymal stem cell proliferation by increasing anti-inflammatory mediators and reducing pro-inflammatory mediators.\n\nBilişsel Egzersiz Terapi Yaklaşımı - BETY (Cognitive Exercise Therapy Approach in english) is an exercise approach based on the biopsychosocial model. BETY consists of innovations in function-oriented body stabilization exercises (FoGSE), chronic pain management (BETY-Nociplastic Pain Management (BETY-NPM)), emotion-mood information management (dance therapy-authentic movement), and sexuality information management. The aim of this study is to investigate the effectiveness of BETY, which is often initiated following intra-articular injections-a treatment frequently chosen for individuals diagnosed with knee osteoarthritis (OA).",[25,284,285,286],"Pain","Pain Management","Exercise","2026-03-23",{"date":289,"type":35},"2026-03-27",{"date":291,"type":35},"2026-01-02",{"date":93,"type":19},{"name":294,"class":42},"Hacettepe University",{"id":296,"slug":4,"hasResults":10,"nctId":297,"briefTitle":298,"officialTitle":298,"acronym":4,"eligibilityCriteria":299,"healthyVolunteers":10,"sex":15,"minAge":77,"maxAge":224,"enrollmentInfo":300,"targetDuration":4,"studyType":20,"phases":302,"briefSummary":303,"conditions":304,"keywords":305,"overallStatus":135,"whyStopped":4,"lastUpdateSubmitDate":308,"lastUpdatePostDateStruct":309,"startDateStruct":311,"completionDateStruct":313,"leadSponsor":315,"locationsCount":43},"100623528","NCT07397806","Home-Based Leg Dexterity Trainer for Management of Knee Osteoarthritis","INCLUSION CRITERIA:\n\n1. Age 40 to 85 years\n2. Ambulatory in home and community settings\n3. History of knee osteoarthritis in one or both knees (Kellgren-Lawrence grade II-IV)\n4. Baseline pain of 3-10 points on the target (i.e., more-affected) knee and a pain differential of at least -2 points on the contralateral knee as exhibited by the worst pain score for the previous week (on the 11-point Numeric Rating Scale, NRS\u002FVisual Analog Scale VAS).\n5. Capacity to personally give informed consent (consent via a legally authorized representative will not be accepted) and who are willing to comply with all study-related procedures and assessments\n\nEXCLUSION CRITERIA:\n\n1. Previous or Planned Knee Surgeries, Procedures, and\u002For Treatments:\n\n   1. Planned surgery on either the contralateral or target knee at any time during the Study period, including pre-and post-training assessments.\n   2. Within 6 months of signing informed consent has received diagnostic arthroscopy of the target knee or arthroscopic surgery (including microfracture and meniscectomy) on the target knee;\n   3. Within 12 weeks of signing informed consent has received intra-articular treatment of the target knee with steroids or hyaluronic acid derivatives;\n   4. Planned intra-articular treatment of the target knee with steroids or hyaluronic acid derivatives on either the contralateral or target knee at any time during the Study period including pre-and post-training assessments.\n   5. History of previous total or partial arthroplasty in the target knee. Partial or total arthroplasty in the contralateral knee is acceptable as long as the surgery was performed at least 6 months prior to enrollment and the operative knee is asymptomatic\n2. Current and\u002For Previous Medical Conditions, Surgeries, and\u002For Procedures:\n\n   1. Within 2 years of signing informed consent, history of active blood disorders (i.e., DVTs, chronic blood clotting, hemophilia, leukemia, myeloma, etc.); or active malignancy of any type or history of a malignancy (with the exception of subjects with a history of treated basal or squamous cell carcinoma).\n   2. Current diagnosis of fibromyalgia based on American College of Rheumatology (ACR) criteria.\n   3. Any active known or suspected systemic autoimmune disease (except for vitiligo, residual auto-immune hypothyroidism requiring hormone replacement only, psoriasis not requiring systemic treatment for two years, conditions not expected to recur in the absence of an external trigger) or any history of systemic inflammatory arthritis such as psoriatic, rheumatoid, ankylosing spondylitis or reactive arthritis.\n   4. Current or prior history of other joint diseases including but not limited to joint dysplasia, crystal-induced arthropathy (such as gout, or calcium pyrophosphate deposition disease evidenced by clinical and\u002For radiographic means), aseptic osteonecrosis, acromegaly, Paget's disease, Ehlers-Danlos Syndrome, Gaucher's disease, Stickler syndrome, joint infection, hemochromatosis, or neuropathic arthropathy of any cause.\n   5. Any medical condition, including findings in laboratory or medical history or in the baseline assessments, that (in the opinion of the Principal Investigator or his designee) constitutes a risk or contraindication for participation in the Study or that could interfere with the Study conduct, endpoint evaluation or prevent the subject from fully participating in all aspects of the Study.\n3. Within 8 weeks of signing informed consent, has used opioid analgesics and is not willing to discontinue these medications through the duration of the study.",{"count":301,"type":19},82,[22],"Rationale:\n\nRoughly 14 million adults aged 60 or older (10% male\u002F13% female) in the United States experience symptoms of knee osteoarthritis (OA). Knee OA pain progressively impacts aging, reducing mobility and increasing morbidity. Nonsurgical self-management of knee OA includes exercise to promote proper knee mechanics, non-steroidal anti-inflammatory drugs (NSAIDs), cortisone injections, and weight loss to reduce pain and retain function. As OA has no cure, self-management progresses to \\~1 million joint replacements per year. Critically, home-based devices are lacking for specifically training the low-level proprioceptive and neuromuscular circuitry for proper knee mechanics in a safe, focused, mechanistic way. Such devices would supplement exercises for strength, mobility, and whole-body loading and movement.\n\nInitially considered a wear-and-tear condition, knee OA is now understood as a complex disease involving inflammatory responses to mechanical loading and neuromuscular feedback loops among pain, joint damage, and dynamic loading. Home-based exercises remain a primary nonpharmacological and nonsurgical approach to managing chronic pain in OA that fundamentally disrupts proprioception and neuromuscular control of the joint, which accelerates articular degeneration.\n\nNeuromuscular Dynamics, LLC has developed a simple, safe, quick, and effective Leg Dexterity System that is portable, wireless, and coupled to HIPAA-compliant cloud analytics. A seated participant uses their foot to compress a platform atop a slender spring, which becomes unstable as it begins to buckle at low forces. The participant must then control their leg dexterity (i.e., via short-latency sensorimotor circuits) to stabilize the unstable dynamic foot-ground interactions. A tablet computer connected to the device provides feedback during use and uploads the participant's activity data to the server for analysis and reporting, accessible to users and clinicians.\n\nThe investigators have successfully tested Leg Dexterity in control participants in multiple publications. The Leg Dexterity test is safe and poses minimal risk as the forces needed to do it are very low, does not involve full weight- bearing maneuvers, and is performed while seated without the risk of falling.\n\nStudy:\n\nThe investigators will conduct a randomized home-based clinical trial in knee OA to demonstrate the efficacy of leg dexterity training to reduce pain and improve function compared to currently prescribed dynamic exercise on a wobble board (a commonly used approach for improving proprioception and balance). Successful completion of this study will justify the adoption of the Leg Dexterity System as an effective at-home supplement to any nonsurgical management of knee OA.\n\nThe investigators propose a longitudinal double-blind dose-matched trial comparing 8 weeks of leg dexterity training (Treatment using a slender, unstable spring system that engages short-latency sensorimotor control, 42 participants) vs. at-home wobble board exercises (Control, 42 participants) at the Steadman Philippon Research Institute.",[25],[133,134,306,307],"exercise","dexterity","2026-02-02",{"date":310,"type":35},"2026-02-09",{"date":312,"type":35},"2025-09-11",{"date":314,"type":19},"2027-12-31",{"name":316,"class":42},"Steadman Philippon Research Institute",{"id":318,"slug":4,"hasResults":10,"nctId":319,"briefTitle":320,"officialTitle":320,"acronym":4,"eligibilityCriteria":321,"healthyVolunteers":10,"sex":15,"minAge":77,"maxAge":322,"enrollmentInfo":323,"targetDuration":4,"studyType":20,"phases":324,"briefSummary":325,"conditions":326,"keywords":329,"overallStatus":135,"whyStopped":4,"lastUpdateSubmitDate":308,"lastUpdatePostDateStruct":332,"startDateStruct":334,"completionDateStruct":335,"leadSponsor":337,"locationsCount":43},"100620713","NCT07361198","Percutaneous Transcatheter Genicular Embolization in Osteoarthritis","Inclusion Criteria:\n\n* Adults aged 40 to 80 years\n* Clinical symptoms consistent with chronic knee pain\n* Radiographically confirmed knee osteoarthritis of Kellgren-Lawrence grade II-IV or persistent knee pain following total knee arthroplasty\n* Insufficient pain relief after standard conservative treatment (e.g., pharmacological therapy, physical therapy, or injections)\n* Ability to understand the study procedures and provide written informed consent \\_ Willingness and ability to comply with the study procedures and follow-up schedule\n\nExclusion Criteria:\n\n* Active local or systemic infection\n* Known coagulation disorders or ongoing anticoagulation that cannot be safely interrupted\n* Significant peripheral arterial disease affecting the lower limbs\n* Known allergy or contraindication to iodinated contrast agents\n* Severe renal impairment\n* History of fibromyalgia or other generalized chronic pain syndromes that may confound pain assessment\n* Pregnancy or breastfeeding","80 Years",{"count":128,"type":19},[22],"This clinical study investigates a minimally invasive treatment called percutaneous transcatheter embolization of knee arteries for patients with chronic knee pain caused by advanced knee osteoarthritis or persistent pain after total knee replacement. Osteoarthritis of the knee is a common degenerative condition that can lead to long-term pain, reduced mobility, and decreased quality of life, and some patients do not achieve sufficient relief with standard treatments.\n\nThe study is based on the hypothesis that targeted embolization of small arteries supplying the inflamed tissues of the knee can safely reduce abnormal blood flow associated with inflammation, leading to pain relief and improved knee function. During the procedure, a thin catheter is guided through the blood vessels to the affected area of the knee, where a temporary embolic agent is administered to reduce pathological blood supply.\n\nThe aim of the study is to evaluate the safety and effectiveness of this procedure by assessing changes in pain intensity, knee function, and quality of life over a follow-up period of up to 24 months. The results of this study may help determine whether this minimally invasive approach can offer a new treatment option for patients who have limited alternatives for managing chronic knee pain",[327,25,328],"Osteoarthritic Knee Pain","Osteoarthitis",[330,133,331],"genicular artery embolisation","MSK embolisation",{"date":333,"type":35},"2026-02-04",{"date":308,"type":35},{"date":336,"type":19},"2029-12-01",{"name":338,"class":42},"Masarykova Nemocnice v Usti nad Labem, Krajska Zdravotni a.s.",{"id":340,"slug":4,"hasResults":10,"nctId":341,"briefTitle":342,"officialTitle":343,"acronym":4,"eligibilityCriteria":344,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":345,"targetDuration":4,"studyType":20,"phases":347,"briefSummary":348,"conditions":349,"keywords":350,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":356,"lastUpdatePostDateStruct":357,"startDateStruct":359,"completionDateStruct":361,"leadSponsor":363,"locationsCount":4},"100611217","NCT07237711","Clinical Investigation of Sensovisc","Clinical Investigation of Sensovisc Sterile Sodium Hyaluronate Gel in the Knee Joint","Inclusion Criteria:\n\n* Patients who have unilateral and\u002For bilateral knee pain for more than 3 months and meet the diagnosis of osteoarthritis according to ACR criteria\n* Diagnosis of Stage II or III knee OA according to the Kellgren and Lawrence (K\\&L) classification, determined by x-rays taken in the last 12 months\n* 40 mm above the pain level determined by VAS during rest for at least 15 days in the month before starting the study (for paracetamol and oral nonsteroidal anti-inflammatory drugs (NSAIDs), taking into account the half-life of the drug)\n* Having a Body Mass Index (BMI) ≤ 40 kg\u002Fm²,\n* Having the mental ability to express pain scores\n* Signing the informed consent form indicating consent to participate in the study\n\nExclusion Criteria:\n\n* Radiological K\\&L stage I and IV\n* Acute inflammatory osteoarthritis attack (KOFUS ≥7)\n* Septic arthritis\n* Secondary OA \\[Synovial chondromatosis or pigmented villonodular synovitis of the knee, Joint diseases (joint dysplasia, aseptic osteonecrosis, acromegaly, Paget's disease, hemophilia, hemochromatosis), Inflammatory diseases (rheumatoid arthritis, gout, infectious arthritis, acute calcium pyrophosphate arthritis)\\]\n* Ipsilateral cruciate or collateral ligament injury in the last 3 months,\n* Corticosteroid injection into the target knee within the last 1 month before the first injection\n* Hyaluronat injection into the target knee within the last 6 months before the first injection\n* Arthroscopy or surgery on the target knee within the last 6 months before the first injection",{"count":346,"type":19},75,[22],"This clinical investigation aims to investigate the safety and performance of Sensovisc.\n\nSensovisc is used to reduce osteoarthritis (OA) related pain in the joints by supporting synovial fluid by intra-articular injection and allowing the synovial fluid to restore its viscoelastic properties. It increases the joint mobility by reducing or eliminating the pain.\n\nThis Clinical Investigation was designed as a cross-sectional, interventional, and prospective study.",[25],[351,352,353,354,355],"viscosupplementation","knee osteoarthritis","hyaluronic acid","dosing","Sensovisc","2025-11-18",{"date":358,"type":35},"2025-11-20",{"date":360,"type":19},"2025-11-25",{"date":362,"type":19},"2026-11-25",{"name":364,"class":42},"Ankara City Hospital Bilkent",{"id":366,"slug":4,"hasResults":10,"nctId":367,"briefTitle":368,"officialTitle":369,"acronym":370,"eligibilityCriteria":371,"healthyVolunteers":10,"sex":15,"minAge":372,"maxAge":4,"enrollmentInfo":373,"targetDuration":4,"studyType":20,"phases":375,"briefSummary":376,"conditions":377,"keywords":379,"overallStatus":135,"whyStopped":4,"lastUpdateSubmitDate":386,"lastUpdatePostDateStruct":387,"startDateStruct":389,"completionDateStruct":391,"leadSponsor":393,"locationsCount":43},"100608222","NCT07198750","\"Bimodal vs Unimodal High-Intensity Pulsed Electromagnetic Field Therapy in Older Adults With Knee Osteoarthritis\"","Effect of High-Intensity Pulsed Electromagnetic Field Therapy as a Bimodal Intervention for Analgesia and Strengthening in Older Adults With Knee Osteoarthritis: A Randomized Double-Blind Controlled Clinical Trial","HIPEMF-OAK","Inclusion Criteria:\n\n* Age ≥ 60\n* Clinical and radiological diagnosis of knee OA grade I-IV\n* Pain ≥ 3 on Numeric Analog Scale for \\>6 months\n* Can walk (with\u002Fwithout aid)\n* Cognitive ability to follow instructions\n* Signed informed consent\n* Availability for 9 treatment sessions and home exercise Exclusion Criteria\n* Prior total knee arthroplasty (unilateral or bilateral)\n* Neurological disorders affecting motor function or cognition (e.g., Parkinson's disease, stroke, moderate to severe dementia)\n* Active inflammatory rheumatic diseases (e.g., rheumatoid arthritis, lupus)\n* Presence of pacemakers, implantable defibrillators, or metallic implants near the treatment area\n* Current use of other physical therapy modalities for pain (e.g., electrotherapy, ultrasound, TENS) outside the study protocol\n* Participation in another clinical trial within the past 3 months\n* Current use of NSAIDs or systemic\u002Flocal corticosteroids (including intra-articular injections)\n* Open wounds or active infections at the treatment site\n* Decompensated cardiac conditions or medical contraindication to exercise\n* Vestibular disorders that affect balance and interfere with functional assessments\n* Uncorrected visual impairment interfering with gait or balance (visual acuity worse than 20\u002F60 in the better eye, assessed by Snellen chart)\n\nWithdrawal Criteria:\n\n* Participants who complete fewer than 7 out of the 9 planned intervention sessions (i.e., less than 80% adherence)\n* Occurrence of serious adverse events related to the intervention that contraindicate continuation\n* Repeated non-compliance with the home exercise program, documented in at least two consecutive weekly follow-up reports\n* Voluntary withdrawal of consent at any time during the study","60 Years",{"count":374,"type":19},64,[22],"This randomized, double-blind clinical trial aims to evaluate the effect of high-intensity pulsed electromagnetic field therapy (HI-PEMF) applied either exclusively on the knee joint or bimodally on the knee and quadriceps, in older adults with knee osteoarthritis. Both groups will also receive a structured home-based exercise program. The primary outcome is pain reduction, and secondary outcomes include functional performance.",[181,59,25,378],"Gonarthrosis",[380,381,382,181,378,383,384,385],"High-Intensity Pulsed Electromagnetic Fields","HI-PEMF","Super Inductive System","Geriatric Rehabilitation","Chronic Pain","Functional Mobility","2025-09-22",{"date":388,"type":35},"2025-09-30",{"date":390,"type":35},"2025-09-15",{"date":392,"type":19},"2026-04-15",{"name":394,"class":42},"Hospital Civil de Guadalajara",{"id":396,"slug":4,"hasResults":10,"nctId":397,"briefTitle":398,"officialTitle":399,"acronym":400,"eligibilityCriteria":401,"healthyVolunteers":10,"sex":15,"minAge":77,"maxAge":402,"enrollmentInfo":403,"targetDuration":4,"studyType":20,"phases":405,"briefSummary":406,"conditions":407,"keywords":410,"overallStatus":135,"whyStopped":4,"lastUpdateSubmitDate":413,"lastUpdatePostDateStruct":414,"startDateStruct":416,"completionDateStruct":418,"leadSponsor":420,"locationsCount":43},"100605347","NCT07161336","Role of Methotrexate in Ultrasound Proven Synovitis in Primary Knee OA","Role of Methotrexate in Ultrasound Proven Synovitis in Patients With Knee Osteoarthritis : A Randomized Controlled Trial","MTX in knee OA","Inclusion Criteria:\n\n* Men and women aged between 40 to 70 years\n* Patients fulfilling American College of Rheumatology (ACR) clinical and radiological criteria for knee OA. (knee pain + at least 3 of 5 that not including \"no palpable warmth\")\n* Knee pain on most days for at least 6 months, with a pain VAS of at least 40mm\n* Radiological grading of OA with Kallgren-Lawrence grade of 2 to 3\n* Patients with the presence of knee synovitis in Musculoskeletal ultrasound\n\nExclusion Criteria:\n\n* Any known inflammatory arthritis\n* BMI \\>= 40 kg\u002Fm2\n* Abnormal renal (e.g. abnormal renal function Creatinine clearance \\\u003C35 ml) hepatic (including active hepatitis B, hepatitis C, abnormal liver function), hematological (e.g. white cell count \\\u003C 4 × 109\u002FL, platelets \\\u003C100 ×109\u002FL, or hemoglobin \\\u003C 9 g\u002FdL), function\n* Use of intra-articular, intramuscular or oral corticosteroids in previous 4 weeks\n* History knee joint surgery, Charcot joint\n* Severe valgus knee deformity (angle of genu valgum \\> 30°)\n* Use of any disease modifying agents (e.g. hydroxychloroquine or sulfasalazine) in previous 3 months\n* Allergic to MTX\n* Pregnant or lactating women","70 Years",{"count":404,"type":19},70,[254],"Background:\n\nOsteoarthritis (OA) is a leading cause of disability worldwide, with limited treatment options and many patients suffering from chronic pain. Modern imaging has revealed that OA involves complex changes in cartilage, subchondral bone, and synovium. Pain in OA is often linked to synovitis, which is common in the condition. Methotrexate (MTX), a proven treatment for synovitis in inflammatory arthritis like rheumatoid arthritis and has a well-known safety profile. The proposal suggests that using MTX may have potential to treat symptomatic knee OA with USG (musculoskeletal ultrasound) proven synovitis by reducing synovitis and as a result, alleviate pain.\n\nObjectives:\n\nTo assess the role of methotrexate in primary knee osteoarthritis associated with ultrasound proven synovitis.\n\nMethods:\n\nThis randomized Controlled trial will be conducted in the department of Rheumatology, Bangladesh Medical University (BMU) from July 2025 to June 2026. A total of 70 patients will be enrolled with primary knee OA diagnosed on the basis of ACR Criteria for Knee OA with informed written consent. MSK USG examinations of knee joint and scoring (OMERACT SCORE) will be performed to detect synovitis by a rheumatologist expert in MSK US. Then randomization will be done into group A and group B following a randomization table, each consisting of 35 patients. Consecutive sampling techniques will be followed. One group will receive MTX (start with 15 mg per week for the first 2 weeks then increase to 20 mg and continue for the remaining period if tolerated) and Both groups of patients will be allowed to take NSAIDs on a requirement basis with documentation and follow non-pharmacological treatment of OA. At the end of 3rd and 6th month pain and functional status will be assessed by WOMAC, VAS and quality of life will be assessed by using Bangla version of SF-12. At the end of 6th month improvement of synovitis will be seen by MSK USG of involved knees with OMERACT scoring. Primary endpoint for efficacy will be assessed at the end of 24th week by WOMAC. Secondary endpoints will be determined by VAS and SF-12. Adverse effects will be assessed by history, physical examinations and investigations. The data will be analyzed by using the latest version SPSS software (Version 29). Results will be recorded using means and standard deviations. Results will be compared among two groups with a 95% confidence interval and a p- value of \\\u003C 0.05 will be considered statistically significant. The degrees of statistical significance between groups will be analyzed by unpaired t test (for quantitative normally distributed data) and Mann Whitney U test if there is skewed distribution. Qualitative data in between groups will be analyzed by the chi square test. Probabilities of associations will be assessed by calculating Pearson's rank correlation coefficient. P-value \\\u003C0.05 will be regarded as statistically significant. The nature, purpose and implication of the study as well as the entire spectrum of benefits and risks of study will be explained to the patients. Privacy and confidentiality of the subject will be maintained. Each patient will enjoy the right to participate and or withdraw from the study at any point of the study period. Ethical clearance will be obtained from the institutional Review Board (IRB) of BMU.",[25,408,409],"Synovitis of Knee","Methotrexate",[411,412,409],"knee OA","synovitis","2025-09-07",{"date":415,"type":35},"2025-09-12",{"date":417,"type":35},"2025-07-30",{"date":419,"type":19},"2026-08-30",{"name":421,"class":42},"Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh",{"id":423,"slug":4,"hasResults":10,"nctId":424,"briefTitle":425,"officialTitle":426,"acronym":427,"eligibilityCriteria":428,"healthyVolunteers":10,"sex":15,"minAge":429,"maxAge":430,"enrollmentInfo":431,"targetDuration":4,"studyType":20,"phases":432,"briefSummary":433,"conditions":434,"keywords":436,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":441,"lastUpdatePostDateStruct":442,"startDateStruct":444,"completionDateStruct":446,"leadSponsor":448,"locationsCount":43},"100603745","NCT07140510","Dinalbuphine Sebacate in Postoperative Pain Control After TKA","Effectiveness of Dinalbuphine Sebacate in Postoperative Pain Control Following Total Knee Arthroplasty: A Randomized Double Blinded Placebo-controlled Trial","Naldebain","Inclusion Criteria:\n\n* Osteoarthritic knee patients underwent unilateral primary TKA\n* Age 50-90 years\n* ASA class I-III\n* Participants understand and consent to the protocol of the trial\n\nExclusion Criteria:\n\n* Morbid obesity (BMI\\>40)\n* Knee osteoarthritis from inflammatory knee arthritis, trauma, infection\n* Previous knee surgery\n* Cognitive disorder\n* Liver disease\n* Allergy to NSAIDs, opioids, sesame oil, and benzyl benzoate\n* CYP3A4 inhibitor and inducer drugs used","50 Years","90 Years",{"count":104,"type":19},[54],"To evaluate the effectiveness of Dinalbuphine Sebacate for controlling subacute pain after total knee arthroplasty",[25,435],"Total Knee Anthroplasty",[437,427,438,439,440],"Dinalbuphine Sebacate","Subacute pain","postoperative pain","total knee arthroplasty","2025-08-18",{"date":443,"type":35},"2025-08-24",{"date":445,"type":19},"2025-10",{"date":447,"type":19},"2026-09",{"name":449,"class":42},"Thammasat University",""]